This first-of-its-kind intravaginal ring is designed to protect against HIV, herpes and unwanted pregnancy. It will be the first device with the potential to offer this protection to be tested in women.
Intravaginal ring providing dual protection is first of its kind to enter a clinical trial
Women’s reproductive health may never be the same, thanks to Northwestern University biomedical engineer Patrick Kiser and his first-of-its-kind intravaginal ring that reliably delivers an antiretroviral drug and a contraceptive for months.
Kiser’s one ring delivers two drugs that do three important things: the device is designed to protect against HIV and herpes as well as unwanted pregnancy. It will be the first device with the potential to offer this protection to be tested in women.
The easy-to-use ring delivers controlled doses of tenofovir (a common antiretroviral drug) and levonorgestrel (a contraceptive) for 90 days. The rings are being manufactured now, and the device soon will undergo its first test in women.
Details of the development of the ring, a device that represents a lot of ‘firsts,’ was published March 5 by PLOS ONE, a peer-reviewed, open-access online journal.
According to the World Health Organization, 35 million people around the world live with HIV, and 222 million women would like to delay or stop childbearing but are not using any method of contraception.
“I suspect women will use the ring primarily for contraception, but they also will benefit from protection against sexually transmitted diseases,” said Kiser, an expert in intravaginal drug delivery. “And for women in the developing world in particular, unwanted pregnancy can have significant health, economic and cultural consequences. We want to motivate women to use this ring.”
The ring, 5.5 centimeters in diameter, is simple yet complex. Kiser and his colleagues worked painstakingly for five years, engineering the three materials that make up the ring and optimizing the device to reliably deliver fixed and efficacious doses of two medicines over a long period of time.
“A lot of engineering has gone into developing the ring,” said Kiser, senior author of the paper. “It represents two Ph.D. theses — one Ph.D. for the larger section containing the antiretroviral drug and another Ph.D. for the smaller section containing the contraceptive.”
Kiser is a faculty member in the department of biomedical engineering at the McCormick School of Engineering and Applied Science and in the department of obstetrics and gynecology at Northwestern University Feinberg School of Medicine.
The ring is easily inserted in the vagina and stays in place for three months. And because the tenofovir is delivered at the site of transmission, the ring — known as the tenofovir levonorgestrel IVR — utilizes a smaller dose than pills. The levonorgestrel released by the ring is the same drug as that used in certain contraceptive pills and in an intrauterine device.
“This system represents a significant advance in vaginal drug delivery technology and is the first in a new class of long-acting multipurpose prevention drug delivery systems,” say the authors in the study. They also report details of the ring’s engineering, safety, stability and drug release.
“The differences between the two drugs are huge, which presented us with a design challenge,” Kiser said. “Tenofovir is highly water soluble while levonorgestrel is highly water insoluble. And the daily dose is different: the ring delivers about 10 milligrams of tenofovir and only 10 micrograms of levonorgestrel. Our scientific hurdle was finding a way to manufacture a dual-purpose ring that got the device into the clinic.”
Tenofovir is taken orally by 3.5 million HIV-infected people worldwide, and it also has been studied as a gel. The drug inhibits HIV and HSV-2 (herpes simplex virus-2) replication in susceptible cells.
Previous studies have demonstrated that antiretroviral drugs can prevent HIV infection, but existing methods for delivering the drug fall short. Pills must be taken daily and require high doses; some women may prefer a longer-lasting method, such as the ring, versus methods used at the time of sex, such as a gel.
Kiser’s combination ring promises much more. The strength of the device stems from its unique polymer construction: its elastomer swells in the presence of fluid (such as that found in the human body), delivering up to 100 times more of the tenofovir than current intravaginal ring technology, which have release rates that decline over time.
“Products only work when they are used,” said co-author David Friend, product development director at CONRAD, which develops reproductive health technologies for low-income countries and is affiliated with Eastern Virginia Medical School.
“By having a ring that can remain in the body for up to 90 days, our hope is that this ring will offer a solution to increase adherence, and therefore provide greater protection against HIV while also preventing pregnancy,” he said.
The Latest on: Birth control
via Google News
The Latest on: Birth control
- FOX News Panel: The Reversible Vasectomy And Male Birth Controlon August 1, 2022 at 2:45 pm
This FOX News panel discusses the possibility of reversible vasectomies as a form of male birth control and this article by Guy Shepherd: The Post Roe two step: First step Freezer; Second step, Vasect ...
- Phexxi® Is a Different Form of Birth Controlon August 1, 2022 at 1:37 pm
Phexxi works naturally with your body to prevent pregnancy by maintaining vaginal pH, no hormones needed — details.
- FDA May Approve First OTC Birth Control Pill In U.S.: More Novel Prescription-To-OTC Switches Could Be On Tapon August 1, 2022 at 6:36 am
FDA may soon approve the first OTC birth control pill in the U.S. And, more novel prescription-to-OTC switches could be on tap. But, the FDA’s proposed plan to facilitate more switches in new ...
- Birth Control Access in Missourion August 1, 2022 at 6:00 am
The unintended pregnancy rate in Missouri is significant, but better contraceptive access is shown to reduce these rates. 3) Unintended and mistimed pregnancies are costly; the annual public cost of ...
- Consider This: Cities tackle rats with electronic traps, carbon monoxide and birth controlon August 1, 2022 at 2:09 am
Northeastern cities are battling a swelling rat population. In Boston alone, rat and rodent complaints climbed 48% from 2019 to 2021, according to the city's 311 data. Consider This cohost Darryl C.
- Pope Francis on birth control: Can the teaching of the Church on contraception change?on July 30, 2022 at 3:49 am
Can the Church’s teaching on birth control change? During Pope Francis’ return flight from Canada, a journalist asked him about the possibility of a development in the Church’s teaching on ...
- Biden admin says birth control is still protected after Supreme Court rulingon July 29, 2022 at 10:14 am
After Roe v. Wade was overturned, the Biden Administration issued a warning to US businesses and health insurance providers that limiting contraception access still violates federal law.
- Men Get Real About Whether They'd Use Male Birth Controlon July 29, 2022 at 2:45 am
After the ruling on Roe v. Wade, the need for men to help prevent pregnancy has never been greater. But would they take hormonal birth control?
- FDA Considers Over-the-Counter Birth Control. Here’s Why It Matters.on July 28, 2022 at 4:53 pm
The FDA first approved the pill in the 1960s, and since then, women have always needed a prescription for birth control.
- Free birth control guaranteed under federal law, Biden administration sayson July 28, 2022 at 1:00 pm
The Biden administration has been receiving complaints from people who say they have not been getting this coverage.
via Bing News
